YOLFTbeta
30

Jilin Province Xidian Pharmaceutical Sci-Tech Development Co.Ltd

301130 · SHE · Healthcare / Drug Manufacturers - Specialty & Generic

23.78CNY-0.38 (-1.57%)

Price History

Full chart

Market Stats

Previous Close24.16
Open24.11
Day Range23.73 – 24.46
52-Week Range21.88 – 39.98
Volume2.18M
Market Cap2.18B
P/E (TTM)356.38
Forward P/E0.00
EPS0.08
Dividend Yield0.51%
Beta0.52
50-Day Avg27.66
200-Day Avg29.19

About

Jilin Province Xidian Pharmaceutical Sci-Tech Development Co.,Ltd engages in the research, development, production, and sales of chemical raw materials and pharmaceutical preparations in China. The company provides drugs for the treatment of anti-anemia, mental disorders, circulatory disorders, anti-psychotic, active pharmaceutical ingredients, and antidepressant medication. It also provides iron supplements and blood tonics; psychotropic drugs; cardiovascular system medication; medication for chronic diseases in the elderly; cancer adjuvant drugs; cardiovascular and cerebrovascular drugs; cold medicine; and other products. The company was founded in 1990 and is headquartered in Panshi, China.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Jun Zhang
  • Employees313
  • HeadquartersNo. 777, Xidian Street, Panshi, China, 132300, China
  • Websitehttps://xidianyy.com

Leadership

  • Mr. Jun ZhangChairman of the Board & GM · b. 1956
  • Mr. Si MengFinancial Director · b. 1987
  • Mr. Shiying XiuDirector & Deputy GM · b. 1961
  • Mr. Yonghong MengDirector & Deputy GM · b. 1960
  • Ms. Yinji ZhangDeputy GM & Secretary · b. 1977
  • Xiang Ru WeiAccounting Supervisor

Financials

Income Statement

Currency: CNY2011-12-312012-12-312013-12-312014-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue115.69M151.31M192.69M203.56M273.51M280.20M324.91M286.32M285.66M255.47M225.49M256.41M234.84M
Growth (%)-+30.78%+27.35%+5.64%+34.36%+2.45%+15.96%-11.88%-0.23%-10.57%-11.73%+13.71%-8.41%
Cost of Revenue48.61M53.14M55.69M29.42M35.24M39.30M47.24M44.32M46.98M47.42M45.52M61.16M55.74M
Gross Profit67.08M98.16M137.00M174.13M238.27M240.90M277.67M242.00M238.68M208.05M179.97M195.24M179.10M
Gross Margin57.98%64.88%71.10%85.55%87.12%85.97%85.46%84.52%83.55%81.44%79.81%76.15%76.26%
Operating Expense36.53M60.91M96.44M119.11M184.09M192.39M212.25M182.75M179.01M155.92M124.32M148.91M161.96M
Operating Income30.55M37.25M40.56M55.02M54.18M48.51M65.42M59.24M59.67M52.13M55.65M46.33M17.14M
Operating Margin26.41%24.62%21.05%27.03%19.81%17.31%20.13%20.69%20.89%20.41%24.68%18.07%7.30%
EBITDA30.76M38.28M41.17M44.58M67.73M66.31M85.12M79.42M77.96M68.95M76.91M69.04M56.88M
EBITDA Margin26.59%25.30%21.37%21.90%24.76%23.66%26.20%27.74%27.29%26.99%34.11%26.93%24.22%
Net Income28.25M37.24M40.32M50.92M45.63M41.36M54.61M49.74M52.02M40.72M50.50M40.27M21.90M
Net Income Margin24.42%24.62%20.92%25.01%16.68%14.76%16.81%17.37%18.21%15.94%22.40%15.71%9.33%
R&D----11.99M20.55M16.56M4.37M13.31M11.74M8.70M10.22M11.25M
R&D as % of Total Revenue----4.38%7.34%5.10%1.52%4.66%4.60%3.86%3.99%4.79%
Interest Expense210.41K47.05K--40.55K35.60K37.90K36.20K35.74K29.34K77.61K107.70K444.83K
Interest Expense % of Total Revenue0.18%0.03%--0.01%0.01%0.01%0.01%0.01%0.01%0.03%0.04%0.19%

Balance Sheet

Currency: CNY2011-12-312012-12-312013-12-312014-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets227.23M239.18M284.49M284.08M470.83M501.64M530.76M550.76M594.61M1.02B1.07B1.06B1.06B
Total Liabilities92.06M77.32M90.06M55.07M89.88M91.45M84.14M78.64M70.47M71.71M84.33M121.41M126.80M
Total Equity135.17M161.86M194.42M229.00M380.95M410.19M446.62M472.12M524.14M945.29M982.86M905.75M904.27M
Cash49.06M54.04M38.65M11.70M93.35M115.89M101.40M107.74M148.63M202.78M334.37M190.68M29.51M
Total Debt12.64M10.00M3.50M3.50M------197.88K10.08M-
Net Debt-36.42M-44.04M-35.15M-8.20M-93.35M-115.89M-101.40M-107.74M-148.63M-202.78M-334.17M-180.60M-

Cash Flow

Currency: CNY2011-12-312012-12-312013-12-312014-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow33.25M36.41M--31.35M66.09M65.93M64.54M59.01M67.23M54.39M54.24M48.62M
Investing Cash Flow-12.37M-12.09M-48.80M-53.74M-3.17M-30.60M-61.94M-30.51M-18.06M-394.41M90.37M-77.57M-
Financing Cash Flow20.70M-19.34M-4.32M-16.94M40.13M-12.95M-18.48M-28.25M-59.61K381.33M-13.17M-120.37M-
Capital Expenditure12.40M12.09M7.83M50.68M44.21M31.09M13.24M14.51M21.18M54.40M123.17M134.97M66.06M
Free Cash Flow20.85M24.32M-7.83M-50.68M-12.86M35.00M52.69M50.03M37.83M12.83M-68.79M-80.73M-17.44M
Dividends Paid29.84M18.64M8.45M16.34M10.83M12.12M18.18M24.24M-10.50M12.93M20.02M20.32M
FCF to OCF62.71%66.79%---41.02%52.96%79.91%77.52%64.10%19.08%-126.48%-148.83%-35.87%
Dividend Paid to FCF143.07%76.66%-107.92%-32.25%-84.19%34.63%34.51%48.45%-81.88%-18.80%-24.79%-116.48%

Earnings

Report DateMar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Feb 23, 2024May 24, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024May 23, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate------------------
EPS Actual0.100.160.140.110.120.260.140.110.170.140.130.080.110.220.11-0.150.12-0.00
Surprise------------------
Timing-------After-hoursAfter-hours---After-hours-----

Key Statistics & Ratios

Market Cap2.18B
Enterprise Value2.04B
Trailing P/E356.38
Forward P/E0.00
Price / Sales10.49
Price / Book2.56
EPS0.08
Book Value11.54
Revenue (TTM)207.96M
Gross Profit (TTM)152.70M
EBITDA37.09M
Profit Margin2.83%
Operating Margin-8.97%
Return on Equity0.46%
Return on Assets-0.23%
Shares Outstanding76.49M
Shares Float39.58M
Beta0.52
Dividend Yield0.51%
Dividend Rate0.15
Payout Ratio1.89%

Dividends

20261×
0.14Jun 1, 2026
20251×
0.26May 29, 2025
20241×
0.26Jun 12, 2024
20231×
0.16Jun 12, 2023
20221×
0.13Jun 30, 2022